Janus激酶抑制剂治疗幼年型皮肌炎:文献综述
本综述检索MEDLINE和Scopus数据库至2023年9月1日,纳入26篇文献共195例接受JAK抑制剂治疗的幼年型皮肌炎患者。最常用托法替尼(57.4%),改善率89.7%;鲁索替尼(27.2%)改善率69.2%;巴瑞替尼(15.4%)改善率92.7%。不良事件报告率72.1%,以感染增加(尤其上呼吸道感染)最常见。作者认为JAK抑制剂可能是难治性JDM的良好治疗选择,但需进一步对照研究。
要点
- 195例JDM患者中,托法替尼使用最多(57.4%),改善率89.7%。
- 巴瑞替尼改善率92.7%,鲁索替尼改善率69.2%。
- 最常见用药指征为难治/复发性皮肤受累(34.7%),其次为肌肉受累(28.6%)。
核心结论
- 作者认为JAK抑制剂可能是良好治疗选择,尤其用于难治性JDM病例,安全性可接受。
- 作者指出需进一步对照研究以建立JAK抑制剂用于JDM最佳方案的更高等级证据。
研究设计与样本
- 文献综述,检索MEDLINE和Scopus数据库从建库至2023年9月1日。
- 共纳入26篇文章,涵盖195例接受JAK抑制剂治疗的JDM患者。
- 患者中位(最小-最大)年龄4.9(1-17)岁,女/男比1.2。
主要发现
- 最常用JAK抑制剂为托法替尼(57.4%),接受托法替尼治疗的患者中89.7%获得改善。
- 鲁索替尼为第二常用JAK抑制剂(27.2%),改善率69.2%。
- 巴瑞替尼使用率15.4%,改善率92.7%。
- 最常见用药指征为难治/复发性皮肤受累(34.7%),其次为难治/复发性肌肉受累(28.6%)。
- 72.1%的患者报告不良事件,感染增加(尤其上呼吸道感染)为最常见副作用。
临床怎么用
- 原文未据此给出推荐。
- 作者认为JAK抑制剂可能是良好治疗选择,尤其用于难治性JDM病例,安全性可接受。
局限性
- 作者指出需进一步对照研究以建立JAK抑制剂用于JDM最佳方案的更高等级证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Janus kinase (JAK) inhibitors have been increasingly used in the treatment of juvenile dermatomyositis (JDM). This review aims to comprehensively analyze previous studies concerning the utilization of JAK inhibitors in JDM patients. METHODS: We conducted a thorough review of MEDLINE and Scopus databases, spanning from their inception to September 1st, 2023, to identify articles involving JDM patients treated with JAK inhibitors. RESULTS: Our literature search yielded 26 articles that encompassed 195 patients with JDM who received JAK inhibitors. The median (min-max) age of the patients was 4.9 (1-17) years (F/M:1.2). The most frequently used JAK inhibitor was tofacitinib (57.4 %), and improvement was achieved in 89.7 % of patients treated with tofacitinib. The improvement rate for ruxolitinib, which was the second most frequently used JAK inhibitor (27.2 %), was 69.2 %. For baricitinib (15.4 %), the improvement rate was 92.7 %. The most prevalent indication for JAK inhibitor use was resistant/recurrent skin involvement (34.7 %) followed by resistant/recurrent muscle involvement (28.6 %). Adverse events were reported in 72.1 % of the patients; an increase in infections (especially upper respiratory tract infections) was the most common side effect. CONCLUSION: Our findings suggest that JAK inhibitors may be a good therapeutic option, particularly in the management of refractory JDM cases with an acceptable safety profile. However, further controlled studies are essential to establish a higher level of evidence for the optimal use of JAK inhibitors in JDM treatment.
引用
- Sener S, Cam V, Ozen S, et al. Treatment with Janus kinase inhibitors in juvenile dermatomyositis: A review of the literature. Semin Arthritis Rheum. 2024. PMID: 38442462. doi:10.1016/j.semarthrit.2024.152426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。